Bavarian Nordic, GSK To Produce Imvamune For Smallpox Vaccine Stockpile
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will collaborate on manufacturing the modified vaccinia Ankara-Bavarian Nordic vaccine for any future HHS contracts. Under the deal, GSK will also market Imvamune in the Americas, Japan and parts of the EU.
You may also be interested in...
Bavarian Nordic Wins HHS Project BioShield Contract For Imvamune Smallpox Vaccine
Five-year contract could be worth $1.6 billion for the third-generation smallpox vaccine, to be stockpiled by the U.S. government for pandemic and terrorism preparedness.
Bavarian Nordic Wins HHS Project BioShield Contract For Imvamune Smallpox Vaccine
Five-year contract could be worth $1.6 billion for the third-generation smallpox vaccine, to be stockpiled by the U.S. government for pandemic and terrorism preparedness.
Acambis Initiates Rolling BLA For Its Cell Culture-Based Smallpox Vaccine
The firm said it expects to complete the filing by April and receive approval by year-end.